Worg is developing immunotherapies based on two technology platforms, the PCFiT for patients with Allergic Rhinitis, Allergic Conjunctivitis and Allergic Asthma, and the Apitopes for patients with autoimmune diseases such as Multiple Sclerosis ("MS"), Graves' disease ("GD"), Uveitis ("UV"), Factor VIII inhibitors ("F8"), Myocarditis, and Rheumatoid Arthritis. Worg owns the global rights of these technologies and programs, and intends to expand its pipeline through collaborations and internal research with an emphasis on immunotherapy. 

PIPELINE EN 2021-10-18 FINAL.jpg